D. E. Van-der-feen, K. Kurakula, E. Tremblay, O. Boucherat, G. P. Bossers et al., Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension, Am J Respir Crit Care Med, vol.200, pp.910-920, 2019.

S. Postel-vinay, K. Herbschleb, C. Massard, V. Woodcock, J. Soria et al., First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity, Eur J Cancer, vol.109, pp.103-110, 2019.

A. Padmanabhan and S. M. Haldar, Drugging transcription in heart failure, J Physiol, 2019.

S. Mumby, N. Gambaryan, C. Meng, F. Perros, M. Humbert et al., Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: implications for pulmonary arterial hypertension, Respirology, vol.22, pp.157-164, 2017.

J. Piquereau, A. Boet, C. Péchoux, F. Antigny, M. Lambert et al., The BET bromodomain inhibitor I-BET-151 induces structural and functional alterations of the heart mitochondria in healthy male mice and rats, Int J Mol Sci, vol.20, p.1527, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02567799

K. A. Sarosiek, C. Fraser, N. Muthalagu, P. D. Bhola, W. Chang et al., Developmental regulation of mitochondrial apoptosis by c-Myc governs age-and tissue-specific sensitivity to cancer therapeutics, Cancer Cell, vol.31, pp.142-156, 2017.